CA2023968C - Living tissue equivalents - Google Patents
Living tissue equivalents Download PDFInfo
- Publication number
- CA2023968C CA2023968C CA002023968A CA2023968A CA2023968C CA 2023968 C CA2023968 C CA 2023968C CA 002023968 A CA002023968 A CA 002023968A CA 2023968 A CA2023968 A CA 2023968A CA 2023968 C CA2023968 C CA 2023968C
- Authority
- CA
- Canada
- Prior art keywords
- collagen
- tissue
- gel
- equivalents
- tissue equivalent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
- C12N5/0698—Skin equivalents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/60—Materials for use in artificial skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
- C12M25/02—Membranes; Filters
- C12M25/04—Membranes; Filters in combination with well or multiwell plates, i.e. culture inserts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/09—Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells
- C12N2502/094—Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells keratinocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1323—Adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/54—Collagen; Gelatin
Abstract
The present invention provides unproved tissue equivalents and methods of making and using such tissue equivalents. The present invention also provides test apparatus incorporating such improved tissue equivalents.
Description
-~ r 2023968 FIELD OF THE INVENTION
This invention relates to methods of preparing and using tissue equivalents comprising (i) a hydrated collagen lattice contracted by a contractile agent, and (ii) a collagen gel in contact with a permeable member. This invention further-relates to test systems incorporating such tissue equivalents.
Tissue equivalents comprising a hydrated collagen lattice contracted by a contractile agent, such as fibroblast cells or blood platelets, to form the tissue equivalent are disclosed in U.S. Patent Nos. 4,485,096;
4,485,097; 4,539,716; 4,546,500; 4,604,346; and 4,837,379, and copending Canadian Patent Application Serial No.
605,116 (hereinafter collectively referred to as "the Patents"). Tissue as used herein comprises any group or layer of cells which together perform one or. more certain functions. Such tissue equivalents include, but are not limited to, equivalents of epithelial tissue, connective tissue, cartilage, bone, organs, glands and blood vessels and comprise living cells and extracellular matrix molecules, principally collagen, and may optionally be provided with components not typically found in normal tissue.
In general such living tissue equivalents are produced by forming a hydrated collagen lattice which is contracted into a living tissue. Examples of contractile agents include fibroblasts cells, smooth muscle cells and blood platelets. A skin-equivalent can be produced from the living connective tissue equivalent substrate by plating keratinocyte cells thereon and providing for their growth.
B
242~g.68 The aforementioned tissue equivalents are populated with cells that can remain alive for long periods of time and can be produced in quantity with the assurance that the units produced will be essentially uniform.
Cells in such tissue equivalents resemble cells of normal tissue in their structural arrangement, in their biosynthetic output, and in their permeability. It should be understood that these tissue equivalents need not be human but may be those of any animal as desired.
Tissue equivalents in accordance with the teachings of the present invention have a broad range of applications including applications in research and development, tissue and organ replacement and testing.
Human skin tissue equivalents permit the growth of normal human epidermal cells that differentiate fully which have not, to date, been obtained by routine culture methods. Such skin tissue equivalents have been extensively used as a permanent skin replacement in animal experiments. The morphological appearance of such skin tissue equivalent is nonaal, constituent cells persist after grafting as shown by genetic marking, and functional performance has been demonstrated. See, e.g., Science, 211: 1052-1054 (1981); J. Invest. Dermatol. 81: 2s-lOs (1983).
Skin tissue equivalents fabricated i~r vitro by the methods disclosed in the Patents bear a close resemblance to natural skin. Such equivalents comprise a multilayered epidermis with well-developed basal cells joined to a dermal layer. The dermal layer comprises a collagen matrix in which dermal fibroblasts are distributed. Cells in the three-dimensional collagen matrix achieve a state of differentiation in many respects similar to that which prevails in vivo.
This invention relates to methods of preparing and using tissue equivalents comprising (i) a hydrated collagen lattice contracted by a contractile agent, and (ii) a collagen gel in contact with a permeable member. This invention further-relates to test systems incorporating such tissue equivalents.
Tissue equivalents comprising a hydrated collagen lattice contracted by a contractile agent, such as fibroblast cells or blood platelets, to form the tissue equivalent are disclosed in U.S. Patent Nos. 4,485,096;
4,485,097; 4,539,716; 4,546,500; 4,604,346; and 4,837,379, and copending Canadian Patent Application Serial No.
605,116 (hereinafter collectively referred to as "the Patents"). Tissue as used herein comprises any group or layer of cells which together perform one or. more certain functions. Such tissue equivalents include, but are not limited to, equivalents of epithelial tissue, connective tissue, cartilage, bone, organs, glands and blood vessels and comprise living cells and extracellular matrix molecules, principally collagen, and may optionally be provided with components not typically found in normal tissue.
In general such living tissue equivalents are produced by forming a hydrated collagen lattice which is contracted into a living tissue. Examples of contractile agents include fibroblasts cells, smooth muscle cells and blood platelets. A skin-equivalent can be produced from the living connective tissue equivalent substrate by plating keratinocyte cells thereon and providing for their growth.
B
242~g.68 The aforementioned tissue equivalents are populated with cells that can remain alive for long periods of time and can be produced in quantity with the assurance that the units produced will be essentially uniform.
Cells in such tissue equivalents resemble cells of normal tissue in their structural arrangement, in their biosynthetic output, and in their permeability. It should be understood that these tissue equivalents need not be human but may be those of any animal as desired.
Tissue equivalents in accordance with the teachings of the present invention have a broad range of applications including applications in research and development, tissue and organ replacement and testing.
Human skin tissue equivalents permit the growth of normal human epidermal cells that differentiate fully which have not, to date, been obtained by routine culture methods. Such skin tissue equivalents have been extensively used as a permanent skin replacement in animal experiments. The morphological appearance of such skin tissue equivalent is nonaal, constituent cells persist after grafting as shown by genetic marking, and functional performance has been demonstrated. See, e.g., Science, 211: 1052-1054 (1981); J. Invest. Dermatol. 81: 2s-lOs (1983).
Skin tissue equivalents fabricated i~r vitro by the methods disclosed in the Patents bear a close resemblance to natural skin. Such equivalents comprise a multilayered epidermis with well-developed basal cells joined to a dermal layer. The dermal layer comprises a collagen matrix in which dermal fibroblasts are distributed. Cells in the three-dimensional collagen matrix achieve a state of differentiation in many respects similar to that which prevails in vivo.
2p23gfi8 For example, resident fibroblasts are synthetically active and enrich the matrix i~ v' o both with collagen, and a number of other molecular species, and exhibit permeability properties typical of a cell in vivo. See, e.g., Collagen Rel. Res. 4: 351-364 (1984). Furthermore, skin tissue equivalents can be pigmented by inclusion of melanocytes that donate pigment to keratinocytes and it has been shown that the process is speeded up in vitro by ultraviolet radiation (J. Invest. Dermatol. 87: 642-647, 1986).
U.S. Patent No. 4,835,102 discloses systems incorporating tissue equivalents that reproduce in vitro many of the physical and biological characteristics of natural tissues and are useful for the study of, for example, tissue cell biology, physiology and pathology. Such systems include apparatus, and kits far determining the interaction of tissue and at least one agent by use of at least one tissue equivalent. Agent includes, but is not limited to, various substances such as chemicals, cosmetics, pharmaceuticals; stimuli, e.g., light or physical injury; and tissue protective agents.
Tissue equivalents can be cast in any desired shape. Skin tissue equivalents for use in skin grafts and in test systems are generally cast as flat sheets and blood vessel equivalents are generally fabricated as a hollow tube or a network of hollow tubes.
However, the natural geometry or configuration of the tissue equivalent may be changed if desired. For example, skin tissue equivalent may be cast as a cylinder rather than as a sheet.
When fibroblast or smooth muscle cells are used as the contractile agent in the production of tissue equivalents, an unrestrained collagen lattice will typically undergo contraction in all dimensions.
Various methods to assist in forming living tissue and 2o239s8 tissue equivalents having controllable configurations and/or dimensions are disclosed in the Patents, e.g., U.S. Patent No. 4,485,096. For example, a collagen lattice may be cast on a stainless steel frame to hold the borders fixed and thus to contract substantially only in the thickness dimension. Other materials which may be used to control the configuration of the tissue equivalent include VELCRO* hook and loop fasteners, textured plastics, and textured TEFLON* (polytetra-fluoroethylene). Although these constraining means are effective, it is preferable in many instances, both in terms of cost and simplicity, to employ constraining means which are not integral with the casting chamber.
In light of the many applications of tissue equivalents, improved tissue equivalents and methods of making such tissue equivalents are being sought.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 is an isometric view, partially broken away, of one apparatus according to the present invention.
Fig. 2 is an exploded isometric view of the apparatus shown in Fig. 1.
Fig. 3 is section along 3-3 through the apparatus shown in Fig. 1.
Fig. 4 is an isometric view, partially broken away, of another apparatus in accordance with the present invention.
Fig. 5 is an exploded view from above of the apparatus shown in Fig. 4.
Fig. 6 is an exploded section along 6-6 through the apparatus shown in Fig. 4.
SUMMARY OF THE INVENTION
The present invention provides tissue equivalents comprising (i) a hydrated collagen lattice contracted by a contractile agent, and (ii) a collagen gel. The present invention also provides tissue equivalents * trade-mark - 4 -~ 2~23~~~
having improved properties including, increased reproducibility from sample to sample in the degree of contraction and, in the case of skin tissue equivalents, in the degree of differentiation of the epidermis.
In some embodiments of the present invention, such tissue equivalents are adjacent to one or more absorbent members including fibrous pads and gels such as agarose.
The present invention also provides methods of making and using such improved tissue equivalents. The methods taught herein also offer advantages over those methods disclosed in the Patents in terms of ease of fabrication and reduced costs of manufacture.
One method in accordance with the present invention whereby a tissue equivalent is formed comprises:
(a) forming a mixture comprising collagen and at least one contractile agent; and (b) applying the mixture obtained in step (a) to a collagen gel, and maintaining the mixture and gel under conditions which permit formation of the tissue equivalent.
The present invention also provides apparatus incorporating such tissue equivalents for determining the interaction of tissue and one or more agents.
In one preferred embodiment of the present invention such apparatus comprises a first and a second region defined by a permeable means provided with a collagen gel on which a tissue equivalent is disposed, whereby the tissue equivalent defines the first region and the permeable member defines the second region.
In yet another preferred embodiment such apparatus comprises at least one tissue equivalent and at least one container for the tissue equivalent, the container comprising:
(i) an inner well comprising a permeable means provided with a collagen gel on which the tissue equivalent is disposed, whereby the permeable means defines the bottom of the inner well, and (ii) an outer well within which the inner well is disposed.
DETAILED DESCRIPTION OF THE INVENTION
The tissue equivalents of the present invention, although similar in both methods of preparation and use to those comprising a hydrated collagen lattice as disclosed in the Patents, further comprise a layer of collagen.
It has been unexpectedly discovered that a collagen lattice cast on a collagen gel in contact with a permeable member does not undergo substantial radial or lateral contraction while contracting in the thickness dimension, thus eliminating the need to anchor the collagen lattice on, e.g., a stainless steel frame, to control radial or lateral contraction. By way of an example, a 24 mm diameter collagen lattice cast as taught in the Patents, but without an anchoring means, would contract radially to a diameter of 5 mm or less.
In contrast, a 24 mm diameter collagen lattice cast on a collagen gel in contact with a permeable member will typically contract radially to a diameter of about 15 mm. The elimination of the anchoring means to control lateral/radial contraction offers advantages in terms of cost reduction and ease of fabrication of tissue equivalents. It should be understood that such anchoring means can be used in conjunction with a collagen gel in contact with a permeable member if desired.
One method of obtaining the tissue equivalents of present invention comprises:
(a) forming a mixture comprising collagen and at least one contractile agent; and ',...
2o239s8 (b) applying the mixture obtained in step (a) to a collagen gel in contact with a permeable member, and maintaining the mixture and gel under conditions which permit formation of the tissue equivalent.
In some embodiments of the present invention, one or more absorbent members, including but not limited to, fibrous pads, cotton pads and gels, agarose, are used in conjunction with the collagen gel described above. Such absorbent members have been found to provide a consistent and level physical support and to promote uniform contact between the tissue equivalent and the cell culture medium. Typically, the absorbent member is adjacent to the surface of the collagen gel opposite the hydrated collagen lattice. Where the absorbent members) is itself a gel, e.g., agarose, the gel may be provided together with a nutrient media to provide nutrients to the tissue equivalent.
The following experimental endpoints have been monitored in tissue equivalents maintained with and without the collagen gel and/or the absorbent member during various phases of development of a skin tissue equivalent:
1. Glucose utilization;
2. The extent and quality of epidermal stratification and cornification;
3. pH of medium.
The observed pH of media obtained from tissue equivalents maintained with the absorbent inember(s) were consistently higher, and closer to physiological pH than tissue equivalents maintained in the absence of these members. In addition, glucose utilization was observed to be generally lower in tissue equivalents maintained with the absorbent member.
,,:,, 20239fi8 It has surprisingly been found that mature cornification is promoted in skin tissue equivalents made by use of the absorbent members) compared to control skin equivalents made without such members.
Although the mechanism by which these absorbent members may influence epidermal differentiation is unknown, it is postulated that such members may act as diffusion barriers, e.g., a permeability barrier, and may filter the medium and/or to retain secreted cellular products in close proximity to the tissue equivalents.
Living skin equivalents of the present invention are prepared as described in the Patents, except that in accordance with the present invention, the hydrated collagen lattice is cast on a collagen gel.
One method of producing a skin tissue equivalent in accordance with the present invention comprises:
(a) forming a mixture comprising collagen and at least one contractile agent:
(b) applying the mixture obtained in step (a) to a collagen gel in contact with a permeable member, and maintaining the mixture and gel under conditions which permit formation of the tissue equivalent; and (c) seeding the tissue equivalent obtained in step (b) with keratinocytes.
By way of background, one convenient protocol for casting the tissue equivalents of the present invention, involves rapidly mixing together an acidic solution of collagen having a pH of about 3 to 4, with nutrient media, adjusting the pH of the resultant solution, if necessary, to about pH 6.6 to pH 7.8, adding fibroblast cells, transferring the resultant mixture (the "casting mixture") into an appropriate mold or casting device having a collagen gel disposed therein and, then, incubating at a temperature _g_ 2~p23968 preferably about 35° to 38°c. It is most convenient to adjust pH and combine the ingredients of the casting mixture simultaneously. However, these steps may be carried out in any desired order, provided that the steps are completed so that the casting mixture can be transferred to a mold for appropriate setting. The collagen fibrils precipitate from the casting mixture as a result of warming the solution and raising the pH to form a hydrated collagen gel contracted by a contractile agent and disposed on a collagen gel.
Although the methods of making living tissue provided by the present invention are applicable to the fabrication of tissue equivalents in general, these methods will be illustrated in connection with the production of skin equivalents for use in skin grafting applications and in test systems incorporating skin equivalents.
Apparatus for, methods of, and kits for determining the interaction of tissues and one or more agents by use of tissue equivalents, including skin tissue equivalents, are described in U.S. Patent No.
U.S. Patent No. 4,835,102 discloses systems incorporating tissue equivalents that reproduce in vitro many of the physical and biological characteristics of natural tissues and are useful for the study of, for example, tissue cell biology, physiology and pathology. Such systems include apparatus, and kits far determining the interaction of tissue and at least one agent by use of at least one tissue equivalent. Agent includes, but is not limited to, various substances such as chemicals, cosmetics, pharmaceuticals; stimuli, e.g., light or physical injury; and tissue protective agents.
Tissue equivalents can be cast in any desired shape. Skin tissue equivalents for use in skin grafts and in test systems are generally cast as flat sheets and blood vessel equivalents are generally fabricated as a hollow tube or a network of hollow tubes.
However, the natural geometry or configuration of the tissue equivalent may be changed if desired. For example, skin tissue equivalent may be cast as a cylinder rather than as a sheet.
When fibroblast or smooth muscle cells are used as the contractile agent in the production of tissue equivalents, an unrestrained collagen lattice will typically undergo contraction in all dimensions.
Various methods to assist in forming living tissue and 2o239s8 tissue equivalents having controllable configurations and/or dimensions are disclosed in the Patents, e.g., U.S. Patent No. 4,485,096. For example, a collagen lattice may be cast on a stainless steel frame to hold the borders fixed and thus to contract substantially only in the thickness dimension. Other materials which may be used to control the configuration of the tissue equivalent include VELCRO* hook and loop fasteners, textured plastics, and textured TEFLON* (polytetra-fluoroethylene). Although these constraining means are effective, it is preferable in many instances, both in terms of cost and simplicity, to employ constraining means which are not integral with the casting chamber.
In light of the many applications of tissue equivalents, improved tissue equivalents and methods of making such tissue equivalents are being sought.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 is an isometric view, partially broken away, of one apparatus according to the present invention.
Fig. 2 is an exploded isometric view of the apparatus shown in Fig. 1.
Fig. 3 is section along 3-3 through the apparatus shown in Fig. 1.
Fig. 4 is an isometric view, partially broken away, of another apparatus in accordance with the present invention.
Fig. 5 is an exploded view from above of the apparatus shown in Fig. 4.
Fig. 6 is an exploded section along 6-6 through the apparatus shown in Fig. 4.
SUMMARY OF THE INVENTION
The present invention provides tissue equivalents comprising (i) a hydrated collagen lattice contracted by a contractile agent, and (ii) a collagen gel. The present invention also provides tissue equivalents * trade-mark - 4 -~ 2~23~~~
having improved properties including, increased reproducibility from sample to sample in the degree of contraction and, in the case of skin tissue equivalents, in the degree of differentiation of the epidermis.
In some embodiments of the present invention, such tissue equivalents are adjacent to one or more absorbent members including fibrous pads and gels such as agarose.
The present invention also provides methods of making and using such improved tissue equivalents. The methods taught herein also offer advantages over those methods disclosed in the Patents in terms of ease of fabrication and reduced costs of manufacture.
One method in accordance with the present invention whereby a tissue equivalent is formed comprises:
(a) forming a mixture comprising collagen and at least one contractile agent; and (b) applying the mixture obtained in step (a) to a collagen gel, and maintaining the mixture and gel under conditions which permit formation of the tissue equivalent.
The present invention also provides apparatus incorporating such tissue equivalents for determining the interaction of tissue and one or more agents.
In one preferred embodiment of the present invention such apparatus comprises a first and a second region defined by a permeable means provided with a collagen gel on which a tissue equivalent is disposed, whereby the tissue equivalent defines the first region and the permeable member defines the second region.
In yet another preferred embodiment such apparatus comprises at least one tissue equivalent and at least one container for the tissue equivalent, the container comprising:
(i) an inner well comprising a permeable means provided with a collagen gel on which the tissue equivalent is disposed, whereby the permeable means defines the bottom of the inner well, and (ii) an outer well within which the inner well is disposed.
DETAILED DESCRIPTION OF THE INVENTION
The tissue equivalents of the present invention, although similar in both methods of preparation and use to those comprising a hydrated collagen lattice as disclosed in the Patents, further comprise a layer of collagen.
It has been unexpectedly discovered that a collagen lattice cast on a collagen gel in contact with a permeable member does not undergo substantial radial or lateral contraction while contracting in the thickness dimension, thus eliminating the need to anchor the collagen lattice on, e.g., a stainless steel frame, to control radial or lateral contraction. By way of an example, a 24 mm diameter collagen lattice cast as taught in the Patents, but without an anchoring means, would contract radially to a diameter of 5 mm or less.
In contrast, a 24 mm diameter collagen lattice cast on a collagen gel in contact with a permeable member will typically contract radially to a diameter of about 15 mm. The elimination of the anchoring means to control lateral/radial contraction offers advantages in terms of cost reduction and ease of fabrication of tissue equivalents. It should be understood that such anchoring means can be used in conjunction with a collagen gel in contact with a permeable member if desired.
One method of obtaining the tissue equivalents of present invention comprises:
(a) forming a mixture comprising collagen and at least one contractile agent; and ',...
2o239s8 (b) applying the mixture obtained in step (a) to a collagen gel in contact with a permeable member, and maintaining the mixture and gel under conditions which permit formation of the tissue equivalent.
In some embodiments of the present invention, one or more absorbent members, including but not limited to, fibrous pads, cotton pads and gels, agarose, are used in conjunction with the collagen gel described above. Such absorbent members have been found to provide a consistent and level physical support and to promote uniform contact between the tissue equivalent and the cell culture medium. Typically, the absorbent member is adjacent to the surface of the collagen gel opposite the hydrated collagen lattice. Where the absorbent members) is itself a gel, e.g., agarose, the gel may be provided together with a nutrient media to provide nutrients to the tissue equivalent.
The following experimental endpoints have been monitored in tissue equivalents maintained with and without the collagen gel and/or the absorbent member during various phases of development of a skin tissue equivalent:
1. Glucose utilization;
2. The extent and quality of epidermal stratification and cornification;
3. pH of medium.
The observed pH of media obtained from tissue equivalents maintained with the absorbent inember(s) were consistently higher, and closer to physiological pH than tissue equivalents maintained in the absence of these members. In addition, glucose utilization was observed to be generally lower in tissue equivalents maintained with the absorbent member.
,,:,, 20239fi8 It has surprisingly been found that mature cornification is promoted in skin tissue equivalents made by use of the absorbent members) compared to control skin equivalents made without such members.
Although the mechanism by which these absorbent members may influence epidermal differentiation is unknown, it is postulated that such members may act as diffusion barriers, e.g., a permeability barrier, and may filter the medium and/or to retain secreted cellular products in close proximity to the tissue equivalents.
Living skin equivalents of the present invention are prepared as described in the Patents, except that in accordance with the present invention, the hydrated collagen lattice is cast on a collagen gel.
One method of producing a skin tissue equivalent in accordance with the present invention comprises:
(a) forming a mixture comprising collagen and at least one contractile agent:
(b) applying the mixture obtained in step (a) to a collagen gel in contact with a permeable member, and maintaining the mixture and gel under conditions which permit formation of the tissue equivalent; and (c) seeding the tissue equivalent obtained in step (b) with keratinocytes.
By way of background, one convenient protocol for casting the tissue equivalents of the present invention, involves rapidly mixing together an acidic solution of collagen having a pH of about 3 to 4, with nutrient media, adjusting the pH of the resultant solution, if necessary, to about pH 6.6 to pH 7.8, adding fibroblast cells, transferring the resultant mixture (the "casting mixture") into an appropriate mold or casting device having a collagen gel disposed therein and, then, incubating at a temperature _g_ 2~p23968 preferably about 35° to 38°c. It is most convenient to adjust pH and combine the ingredients of the casting mixture simultaneously. However, these steps may be carried out in any desired order, provided that the steps are completed so that the casting mixture can be transferred to a mold for appropriate setting. The collagen fibrils precipitate from the casting mixture as a result of warming the solution and raising the pH to form a hydrated collagen gel contracted by a contractile agent and disposed on a collagen gel.
Although the methods of making living tissue provided by the present invention are applicable to the fabrication of tissue equivalents in general, these methods will be illustrated in connection with the production of skin equivalents for use in skin grafting applications and in test systems incorporating skin equivalents.
Apparatus for, methods of, and kits for determining the interaction of tissues and one or more agents by use of tissue equivalents, including skin tissue equivalents, are described in U.S. Patent No.
4,835,102. Tissue equivalents for such applications may also advantageously further comprise, in accordance with the present invention, a collagen gel in contact with a permeable member.
Referring to the drawings, Figs. 1-3 illustrate one embodiment of an apparatus for determining the interaction of skin and one or more agents by use of skin tissue equivalents in accordance with the present invention, wherein multiple containers 10,22 having tissue equivalents of the present invention disposed therein are provided in a base or holder. The apparatus shown in Figs. 1-3 is also provided with a cover means 2. In some embodiments a covering (not ,4,~ 20..23968 shown) is provided for each container 10,20. The covering is selected from any biocompatible material which will hold a seal on the container. Acceptable covering materials include foils and barrier films which may be sealed to the apparatus by means of an adhesive or heat. A heat sealable polyester film is particularly useful in the practice of the present invention.
The containers for the tissue equivalents comprise an outer container 10 and an inner container 20. The inner container 20 is provided with a rim 50 to provide means for positioning the inner container 20 in the outer container 10 thereby defining an outer area 14 and an inner area 22. The inner container 20 is provided with a skin tissue equivalent 26, 28 disposed on a collagen gel 25 which is in turn disposed adjacent a permeable member 24. The permeable member is sealably attached to the inner container 20 to form the bottom surface thereof. The skin tissue equivalent comprises two layers 26, 28, layer 28 comprising an epidermal layer, layer 26 comprising a dermal layer.
In some embodiments, a sealing member 30 provides a seal between the inner wall of the inner container 20 and the skin equivalent 26, 28 and covers the perimeter of the collagen gel 25 in the case where the outer edge of the tissue equivalent 26, 28 is positioned inward of the collagen gel 25. In the embodiments pictured in the Figures, the container 10 is provided with an opening 21 which provide access to the outer area 14.
The apparatus depicted in Fig. 3 is further provided with a absorbent member 32. In yet other embodiments, the outer chamber 14 may have a gel, not shown, disposed therein.
Figs. 4-6 illustrate another embodiment of an apparatus for determining the interaction of tissue and one or more agents by use of tissue equivalents in accordance with the present invention. Elements similar to those in other described embodiments are indicated by the same numeral. In this embodiment, the outer well 10 is square and is provided with elevated sections 60 in the bottom on which the inner container 20 may be positioned. The outer well 10 rather than projecting upwardly from the bottom of the apparatus is formed as a pocket from the top of the apparatus.
The outer well 10 is provided with nutrient medium for the tissue equivalent. Such media are known in the art. Preferred serum free nutrient media are disclosed in co-pending Canadian Patent App. Ser. No. 2018228-8. The volume of medium must be selected to fill the outer container 14 to an appropriate level so as not to build up a head of pressure which would force the medium through the permeable member 24, the collagen gel 25, the tissue equivalent 26, 28, into the inner container 20.
In some embodiments of the present invention, the outer container 10 is provided with an absorbent member 32 which is disposed in the outer container 10 so as to contact the outer~surface of the permeable member 21.
The absorbent member 32 must be compatible with living tissue equivalents. Preferred materials far the absorbent member include cotton, polyester and rayon.
A particularly preferred material is absorbent cotton.
In general, it is preferred that the absorbent member be free of additives such as detergents.
In other embodiments of the present invention., the outer well 10 is provided with a gel (not shown), such as agarose, which serves to trap the medium. Because the agarose gel can be added up to just below the level of the openings 24, a greater amount of nutrient medium is made available to the tissue equivalent and nutrient supply to the tissue equivalent 26, 28 is not B
Zo239sa exhausted as quickly. The use of such gels provides benefits in storing and shipping the apparatus of the present invention in terms of minimizing leakage of the media and resultant potential contamination of the tissue equivalent.
The outer 10 and inner 20 containers may be made of any desired material which does not react with or have an undesirable effect on the components of the assay, including the tissue equivalent. For example, the casting mixture for the living tissue equivalent must not adhere to the walls of the inner container during contraction so as to interfere with formation of the tissue equivalent.
It has been found that methods used to sterilize the inner container 20 may impact adherence of the tissue equivalent. For example, the forming tissue will adhere to polystyrene, one preferred material for the inner container, when it is sterilized by electron beam but not when it is sterilized by ethylene oxide.
In contrast, K-RESIN butadiene-styrene~polymer, an alloy of polystyrene and butadiene and a particularly preferred material for the inner container, may be sterilized by electron beam without causing the forming tissue equivalent to adhere. (K-RESIN is a trademark of Phillips Petroleum.) In some embodiments, it is desirable that the containers be made so that the tissue equivalent is visible through the container, e.g., through the walls of the container or through a Window in the container.
Preferred materials for the container 10 include polystyrene and PETG.
The inner container 20 may be of any shape and volume which will accommodate the size and shape of the desired tissue equivalent. The dimensions of the container will again depend upon the size and shape of the desired tissue equivalent and the desired assay volumes. For example, a container having an outer B
,,,~ 2023968 diameter of about 25 mm and a volume of about 5 ml is useful in practicing the present invention. In the embodiment shown in Figs. 1-3, multiple containers are provided in a base or holder.
The permeable member 24 must have sufficient strength to support the collagen gel 25 and the tissue equivalent 26, 28. Porous membranes are useful in the practice of the present invention. The pore size of such membranes is selected so as to provide attachment for the collagen gel 25. Preferred membranes are hydrophylic, have a thickness of about 1 to 10 mm, and pore diameters ranging from about 1 to about 10~.
Preferred materials for the permeable member 24 include polycarbonate. A particularly preferred permeable member is a polycarbonate membrane, preferably free of wetting agents, commercially available from Nuclepore and having a pore size of about 3 to 10~c.
The sealing means 30 may be made of any material which is inert to the conditions of the assay and the tissue equivalents being used, as well as provides a good seal between the inner container 20 and the tissue equivalent. Preferred materials include polyethylene, TEFLON*. polycarbonate and nylon. The sealing means is especially useful where it is desired to keep the contents of the outer container separated from any solution or substance applied to the epidermis 25, e.g., when measuring the diffusion or permeation of a substance through a tissue equivalent.
Both the tissue equivalents and the collagen gel in accordance with the present invention may be prepared using collagen derived from skin and tendon, including rat tail tendon, calf skin collagen, and calf extensor tendon. Other sources of collagen would be suitable.
A particularly preferred collagen composition derived from calf common digital extensor tendon and methods of * trade-mark B
deriving such collagen compositions are disclosed in co-pending Canadian Patent Application Serial No.
2023970-1 filed on even date herewith.
In one method of the present invention, the collagen gel 25 is prepared from a collagen composition comprising collagen at about 0.5 to 2.0 mg/ml, preferably about 0.9 to 1.1 mg/ml and nutrient media.
This collagen composition is added to the inner container 20 and maintained under conditions which permit the collagen composition to set and form a collagen gel of suitable dimensions, typically about 1 to 5 mm thick, a preferred thickness range being about 2 to about 3 mm. The collagen gel 25 is preferably thick enough so that a portion remains acellular as cells migrate from the tissue equivalent into the collagen gel and thin enough so that the tissue equivalent is not undesirably removed from the nutrient source provided in outer container 10.
A denaal equivalent is next cast on the collagen gel using procedures in accordance with the Patents and as described hereinafter. A casting mixture containing collagen and fibroblasts is added to inner container 20 over the collagen gel 25 and maintained under conditions which enable the tissue equivalent to form.
As the tissue equivalent forms on the collagen gel 25, it contracts radially. However, the collagen gel 25 prevents excessive radial contraction of the tissue equivalent without the need of mechanical restraining means such as textured metals and plastics or VELCRO * .
Typically, the sides of the tissue equivalent 26 slope towards the outer periphery of the collagen gel 25 to form a mesa as shown in Figs. 3 and 6 at 52. The tissue equivalent 26 is now seeded with epithelial cells to form the epidermal layer 28. The epidermal cells are seeded in culture medium at a concentration * trade-mark .2p2396w8 v:
of at about 0.3 x 106 to 30 x 106 cells/ml. The volume of epidermal cells seeded will depend upon the size of the mesa.
The concentration of collagen, the number of cells and the volume of the casting mixture can be controlled to optimize the diameter and thickness of the living tissue equivalent. The casting mixture comprises cells at a concentration of about 1.25 to 5x104 cells/ml and collagen at about 0.5 to 2.0 mg/ml in a nutrient medium. A preferred cell concentration is about 2.5 x 104 cells/ml. It has been found that the ratio of the volume of the casting mixture for the tissue equivalent to the volume of the casting mixture for the collagen gel has an effect upon cell viability and differentiation. Useful ratios, v/v, of tissue equivalent casting mixture to collagen gel casting mixture are about 3:1 to 1:3. A preferred ratio wherein the cell concentration in the collagen lattice is at about 2.5 x 104 cells/ml is 3:1.
The invention will be further understood with reference to the following examples, which are purely exemplary in nature, and are not meant to be utilized to limit the scope of the invention.
Materials used in the following examples were obtained from the sources indicated in the examples or made in accordance with the indicated publications.
Sterile procedures were used throughout the Examples.
The tissue equivalents were maintained under 10% C02 in the incubator and sterile procedures were used throughout.
Example I: Preparation of Skin Tissue Equivalent Test Systems A. An apparatus similar to that shown in Fig 4. was used in conducting the work described hereinafter. The cover is removed for conducting operation but is 2o239sa otherwise kept in place to maintain sterility.
Pertinent information regarding the apparatus is listed below:
Outer container 10: diameter 38 mm capacity 35 ml Inner container 20: diameter 24 mm capacity 4 ml Permeable member 24: Polycarbonate membrane from Nuclepore, pore size 3~, thickness 5~c.
B. A collagen gel was formed on the permeable member 24 as follows:
(1) Premix:
lOX MFM 16.2m1 L-glutamine (200 mM) 1.6m1 gentamycin (50mg/ml) 0.2m1 Fetal bovine serum l8.Oml Sodium bicarbonate (7I.2mg/ml) 5.Om1 The stack solutions were mixed at 37oC, combining in the above sequence, and stored at 4oC for approximately 30 min. in 50 ml. tube (not gassed).
(2) 27.8 g of a 1 mg/ml collagen solution (extracted by acid from calf common digital extensor tendon) in 0.05% v/v acetic acid, was weighed out into a 50 ml tube and stored 4°C for 30 min..
(3) 8.2 ml of the pre-mix described above and 4 ml of DMEM complete (containing 10% FBS, 4mM L-glutamine, 50 ug/ml gentamycin) was added (and 1 ml aliquots pipetted into the inner container 20 and allowed to.~gel in a hood.
C. Tissue equivalents were cast with human dermal fibroblasts and seeded with human epidermal (epithelial) cells as described below. A general description of procedures and reagents.may also be found in the Patents and aforementioned Canadian Patent copending application Serial No. 2018228-8.
F 2023968.
w y~ 'i L~~
(1) Casting mixture:
8.2 ml of the pre-mix described above was added to 27.8g of a 1 mg/ml collagen solution in 0.05% v/v acetic acid, as described in step A(2) above, and 4 ml of human dermal fibroblasts (2.5 x 10~ cells/ml) were combined. 3 ml aliquots were pipetted into the container 20 over the collagen gel formed in step B(2) above and allowed to gel. 4.5 ml DMEM complete was added to the outside container 20 and then incubated at 36oC/10% C02 typically for 4-8 days.
The following medium was used:
Components mSBM
Hydrocortisone l.luM
Insulin 5 ~g/ml Transferrrin 5 ~Cg/ml Triiodothyronine 20 pM
Ethanolamine 1 x 10-4M
O-phosphorylethanolamine 1 x 10-4M
Adenine 0.18 mM
Progesterone 2 x 10-9M
Selenium 5.26 x 10-8M
Bovine Serum ~ 0.3%
Epidermal Growth Factor 10 ng/ml Calcium Free DMEM 75%
Ham's F-12 25%
Two other media used were identical with mSBM
except as noted below:
cSBM mainSBM
Progesterone 0 0 Bovine Serum 2.0% 1%
Epidermal Growth Factor 1 ng/ml 1 ng/ml Calcium Free DMEM 50% 50%
Ham's F-12 50% 50%
In some instances calcium chloride was added to the media at 1.8 mM. This is indicated as medium plus calcium, e.g., mSBM plus calcium.
D. Epidermalization was initiated at 6 days after casting the tissue equivalent.
(1) Eoidermalizinct The medium of step C above was removed from both the inside 20 and outside 10 containers. A 50 ~C1 - - 2x23968 l suspension of human epidermal cells (3.33 x 106 cells/ml) was placed on the tissue equivalent formed above in step C above. The container was then incubated at 36°C and 10% C02 for 4 hours. 12.0 ml of mSBM
was then added to the outside chamber and 4 ml to the well. The apparatus was then returned to the same incubator.
(2) n;Fferentiating At 2 days post epidermalization the medium was removed and replaced with mSBM plus calcium.
(3) Airlifting At 5 days post epidermalization, the following procedure was performed:
Medium was removed from inside and outside chambers.
The inner container 20 was removed and two volumes cSBM
plus calcium soaked cotton pads were positioned in the bottom of the outer chamber 10 and 9.0 ml of cSBM plus calcium added. The inner container 20 was then replaced and the apparatus incubated at 35.5°C and 10% C02.
(4) Maintaining Every 4 days the medium was removed and replaced with fresh mainSBM plus calcium.
Example II:
Preparation of Test Systems Incornoratina Aaarose A 2% agarose solution in water was sterilized by autoclaving, cooled to 40°C and mixed with an equal volume of 2 concentrated mainSBM. The absorbent cotton pads were removed and 13 ml of the mixture was poured into the outer area 14, allowed to set at 36oC (10%
Co2) and the apparatus returned to the incubator for storage prior to shipment.
It is understood that the examples and embodiments described herein are for illustrative purposes only, and that various modifications or changes in light thereof ._ ~ 2.023~9ss that will be suggested to persons skilled in the art are to be included in the spirit and purview of this application and the scope of the approved claims.
Referring to the drawings, Figs. 1-3 illustrate one embodiment of an apparatus for determining the interaction of skin and one or more agents by use of skin tissue equivalents in accordance with the present invention, wherein multiple containers 10,22 having tissue equivalents of the present invention disposed therein are provided in a base or holder. The apparatus shown in Figs. 1-3 is also provided with a cover means 2. In some embodiments a covering (not ,4,~ 20..23968 shown) is provided for each container 10,20. The covering is selected from any biocompatible material which will hold a seal on the container. Acceptable covering materials include foils and barrier films which may be sealed to the apparatus by means of an adhesive or heat. A heat sealable polyester film is particularly useful in the practice of the present invention.
The containers for the tissue equivalents comprise an outer container 10 and an inner container 20. The inner container 20 is provided with a rim 50 to provide means for positioning the inner container 20 in the outer container 10 thereby defining an outer area 14 and an inner area 22. The inner container 20 is provided with a skin tissue equivalent 26, 28 disposed on a collagen gel 25 which is in turn disposed adjacent a permeable member 24. The permeable member is sealably attached to the inner container 20 to form the bottom surface thereof. The skin tissue equivalent comprises two layers 26, 28, layer 28 comprising an epidermal layer, layer 26 comprising a dermal layer.
In some embodiments, a sealing member 30 provides a seal between the inner wall of the inner container 20 and the skin equivalent 26, 28 and covers the perimeter of the collagen gel 25 in the case where the outer edge of the tissue equivalent 26, 28 is positioned inward of the collagen gel 25. In the embodiments pictured in the Figures, the container 10 is provided with an opening 21 which provide access to the outer area 14.
The apparatus depicted in Fig. 3 is further provided with a absorbent member 32. In yet other embodiments, the outer chamber 14 may have a gel, not shown, disposed therein.
Figs. 4-6 illustrate another embodiment of an apparatus for determining the interaction of tissue and one or more agents by use of tissue equivalents in accordance with the present invention. Elements similar to those in other described embodiments are indicated by the same numeral. In this embodiment, the outer well 10 is square and is provided with elevated sections 60 in the bottom on which the inner container 20 may be positioned. The outer well 10 rather than projecting upwardly from the bottom of the apparatus is formed as a pocket from the top of the apparatus.
The outer well 10 is provided with nutrient medium for the tissue equivalent. Such media are known in the art. Preferred serum free nutrient media are disclosed in co-pending Canadian Patent App. Ser. No. 2018228-8. The volume of medium must be selected to fill the outer container 14 to an appropriate level so as not to build up a head of pressure which would force the medium through the permeable member 24, the collagen gel 25, the tissue equivalent 26, 28, into the inner container 20.
In some embodiments of the present invention, the outer container 10 is provided with an absorbent member 32 which is disposed in the outer container 10 so as to contact the outer~surface of the permeable member 21.
The absorbent member 32 must be compatible with living tissue equivalents. Preferred materials far the absorbent member include cotton, polyester and rayon.
A particularly preferred material is absorbent cotton.
In general, it is preferred that the absorbent member be free of additives such as detergents.
In other embodiments of the present invention., the outer well 10 is provided with a gel (not shown), such as agarose, which serves to trap the medium. Because the agarose gel can be added up to just below the level of the openings 24, a greater amount of nutrient medium is made available to the tissue equivalent and nutrient supply to the tissue equivalent 26, 28 is not B
Zo239sa exhausted as quickly. The use of such gels provides benefits in storing and shipping the apparatus of the present invention in terms of minimizing leakage of the media and resultant potential contamination of the tissue equivalent.
The outer 10 and inner 20 containers may be made of any desired material which does not react with or have an undesirable effect on the components of the assay, including the tissue equivalent. For example, the casting mixture for the living tissue equivalent must not adhere to the walls of the inner container during contraction so as to interfere with formation of the tissue equivalent.
It has been found that methods used to sterilize the inner container 20 may impact adherence of the tissue equivalent. For example, the forming tissue will adhere to polystyrene, one preferred material for the inner container, when it is sterilized by electron beam but not when it is sterilized by ethylene oxide.
In contrast, K-RESIN butadiene-styrene~polymer, an alloy of polystyrene and butadiene and a particularly preferred material for the inner container, may be sterilized by electron beam without causing the forming tissue equivalent to adhere. (K-RESIN is a trademark of Phillips Petroleum.) In some embodiments, it is desirable that the containers be made so that the tissue equivalent is visible through the container, e.g., through the walls of the container or through a Window in the container.
Preferred materials for the container 10 include polystyrene and PETG.
The inner container 20 may be of any shape and volume which will accommodate the size and shape of the desired tissue equivalent. The dimensions of the container will again depend upon the size and shape of the desired tissue equivalent and the desired assay volumes. For example, a container having an outer B
,,,~ 2023968 diameter of about 25 mm and a volume of about 5 ml is useful in practicing the present invention. In the embodiment shown in Figs. 1-3, multiple containers are provided in a base or holder.
The permeable member 24 must have sufficient strength to support the collagen gel 25 and the tissue equivalent 26, 28. Porous membranes are useful in the practice of the present invention. The pore size of such membranes is selected so as to provide attachment for the collagen gel 25. Preferred membranes are hydrophylic, have a thickness of about 1 to 10 mm, and pore diameters ranging from about 1 to about 10~.
Preferred materials for the permeable member 24 include polycarbonate. A particularly preferred permeable member is a polycarbonate membrane, preferably free of wetting agents, commercially available from Nuclepore and having a pore size of about 3 to 10~c.
The sealing means 30 may be made of any material which is inert to the conditions of the assay and the tissue equivalents being used, as well as provides a good seal between the inner container 20 and the tissue equivalent. Preferred materials include polyethylene, TEFLON*. polycarbonate and nylon. The sealing means is especially useful where it is desired to keep the contents of the outer container separated from any solution or substance applied to the epidermis 25, e.g., when measuring the diffusion or permeation of a substance through a tissue equivalent.
Both the tissue equivalents and the collagen gel in accordance with the present invention may be prepared using collagen derived from skin and tendon, including rat tail tendon, calf skin collagen, and calf extensor tendon. Other sources of collagen would be suitable.
A particularly preferred collagen composition derived from calf common digital extensor tendon and methods of * trade-mark B
deriving such collagen compositions are disclosed in co-pending Canadian Patent Application Serial No.
2023970-1 filed on even date herewith.
In one method of the present invention, the collagen gel 25 is prepared from a collagen composition comprising collagen at about 0.5 to 2.0 mg/ml, preferably about 0.9 to 1.1 mg/ml and nutrient media.
This collagen composition is added to the inner container 20 and maintained under conditions which permit the collagen composition to set and form a collagen gel of suitable dimensions, typically about 1 to 5 mm thick, a preferred thickness range being about 2 to about 3 mm. The collagen gel 25 is preferably thick enough so that a portion remains acellular as cells migrate from the tissue equivalent into the collagen gel and thin enough so that the tissue equivalent is not undesirably removed from the nutrient source provided in outer container 10.
A denaal equivalent is next cast on the collagen gel using procedures in accordance with the Patents and as described hereinafter. A casting mixture containing collagen and fibroblasts is added to inner container 20 over the collagen gel 25 and maintained under conditions which enable the tissue equivalent to form.
As the tissue equivalent forms on the collagen gel 25, it contracts radially. However, the collagen gel 25 prevents excessive radial contraction of the tissue equivalent without the need of mechanical restraining means such as textured metals and plastics or VELCRO * .
Typically, the sides of the tissue equivalent 26 slope towards the outer periphery of the collagen gel 25 to form a mesa as shown in Figs. 3 and 6 at 52. The tissue equivalent 26 is now seeded with epithelial cells to form the epidermal layer 28. The epidermal cells are seeded in culture medium at a concentration * trade-mark .2p2396w8 v:
of at about 0.3 x 106 to 30 x 106 cells/ml. The volume of epidermal cells seeded will depend upon the size of the mesa.
The concentration of collagen, the number of cells and the volume of the casting mixture can be controlled to optimize the diameter and thickness of the living tissue equivalent. The casting mixture comprises cells at a concentration of about 1.25 to 5x104 cells/ml and collagen at about 0.5 to 2.0 mg/ml in a nutrient medium. A preferred cell concentration is about 2.5 x 104 cells/ml. It has been found that the ratio of the volume of the casting mixture for the tissue equivalent to the volume of the casting mixture for the collagen gel has an effect upon cell viability and differentiation. Useful ratios, v/v, of tissue equivalent casting mixture to collagen gel casting mixture are about 3:1 to 1:3. A preferred ratio wherein the cell concentration in the collagen lattice is at about 2.5 x 104 cells/ml is 3:1.
The invention will be further understood with reference to the following examples, which are purely exemplary in nature, and are not meant to be utilized to limit the scope of the invention.
Materials used in the following examples were obtained from the sources indicated in the examples or made in accordance with the indicated publications.
Sterile procedures were used throughout the Examples.
The tissue equivalents were maintained under 10% C02 in the incubator and sterile procedures were used throughout.
Example I: Preparation of Skin Tissue Equivalent Test Systems A. An apparatus similar to that shown in Fig 4. was used in conducting the work described hereinafter. The cover is removed for conducting operation but is 2o239sa otherwise kept in place to maintain sterility.
Pertinent information regarding the apparatus is listed below:
Outer container 10: diameter 38 mm capacity 35 ml Inner container 20: diameter 24 mm capacity 4 ml Permeable member 24: Polycarbonate membrane from Nuclepore, pore size 3~, thickness 5~c.
B. A collagen gel was formed on the permeable member 24 as follows:
(1) Premix:
lOX MFM 16.2m1 L-glutamine (200 mM) 1.6m1 gentamycin (50mg/ml) 0.2m1 Fetal bovine serum l8.Oml Sodium bicarbonate (7I.2mg/ml) 5.Om1 The stack solutions were mixed at 37oC, combining in the above sequence, and stored at 4oC for approximately 30 min. in 50 ml. tube (not gassed).
(2) 27.8 g of a 1 mg/ml collagen solution (extracted by acid from calf common digital extensor tendon) in 0.05% v/v acetic acid, was weighed out into a 50 ml tube and stored 4°C for 30 min..
(3) 8.2 ml of the pre-mix described above and 4 ml of DMEM complete (containing 10% FBS, 4mM L-glutamine, 50 ug/ml gentamycin) was added (and 1 ml aliquots pipetted into the inner container 20 and allowed to.~gel in a hood.
C. Tissue equivalents were cast with human dermal fibroblasts and seeded with human epidermal (epithelial) cells as described below. A general description of procedures and reagents.may also be found in the Patents and aforementioned Canadian Patent copending application Serial No. 2018228-8.
F 2023968.
w y~ 'i L~~
(1) Casting mixture:
8.2 ml of the pre-mix described above was added to 27.8g of a 1 mg/ml collagen solution in 0.05% v/v acetic acid, as described in step A(2) above, and 4 ml of human dermal fibroblasts (2.5 x 10~ cells/ml) were combined. 3 ml aliquots were pipetted into the container 20 over the collagen gel formed in step B(2) above and allowed to gel. 4.5 ml DMEM complete was added to the outside container 20 and then incubated at 36oC/10% C02 typically for 4-8 days.
The following medium was used:
Components mSBM
Hydrocortisone l.luM
Insulin 5 ~g/ml Transferrrin 5 ~Cg/ml Triiodothyronine 20 pM
Ethanolamine 1 x 10-4M
O-phosphorylethanolamine 1 x 10-4M
Adenine 0.18 mM
Progesterone 2 x 10-9M
Selenium 5.26 x 10-8M
Bovine Serum ~ 0.3%
Epidermal Growth Factor 10 ng/ml Calcium Free DMEM 75%
Ham's F-12 25%
Two other media used were identical with mSBM
except as noted below:
cSBM mainSBM
Progesterone 0 0 Bovine Serum 2.0% 1%
Epidermal Growth Factor 1 ng/ml 1 ng/ml Calcium Free DMEM 50% 50%
Ham's F-12 50% 50%
In some instances calcium chloride was added to the media at 1.8 mM. This is indicated as medium plus calcium, e.g., mSBM plus calcium.
D. Epidermalization was initiated at 6 days after casting the tissue equivalent.
(1) Eoidermalizinct The medium of step C above was removed from both the inside 20 and outside 10 containers. A 50 ~C1 - - 2x23968 l suspension of human epidermal cells (3.33 x 106 cells/ml) was placed on the tissue equivalent formed above in step C above. The container was then incubated at 36°C and 10% C02 for 4 hours. 12.0 ml of mSBM
was then added to the outside chamber and 4 ml to the well. The apparatus was then returned to the same incubator.
(2) n;Fferentiating At 2 days post epidermalization the medium was removed and replaced with mSBM plus calcium.
(3) Airlifting At 5 days post epidermalization, the following procedure was performed:
Medium was removed from inside and outside chambers.
The inner container 20 was removed and two volumes cSBM
plus calcium soaked cotton pads were positioned in the bottom of the outer chamber 10 and 9.0 ml of cSBM plus calcium added. The inner container 20 was then replaced and the apparatus incubated at 35.5°C and 10% C02.
(4) Maintaining Every 4 days the medium was removed and replaced with fresh mainSBM plus calcium.
Example II:
Preparation of Test Systems Incornoratina Aaarose A 2% agarose solution in water was sterilized by autoclaving, cooled to 40°C and mixed with an equal volume of 2 concentrated mainSBM. The absorbent cotton pads were removed and 13 ml of the mixture was poured into the outer area 14, allowed to set at 36oC (10%
Co2) and the apparatus returned to the incubator for storage prior to shipment.
It is understood that the examples and embodiments described herein are for illustrative purposes only, and that various modifications or changes in light thereof ._ ~ 2.023~9ss that will be suggested to persons skilled in the art are to be included in the spirit and purview of this application and the scope of the approved claims.
Claims (10)
1. A tissue equivalent comprising:
(a) a hydrated collagen lattice contracted by a contractile agent; and (b) a collagen gel in contact with a permeable member.
(a) a hydrated collagen lattice contracted by a contractile agent; and (b) a collagen gel in contact with a permeable member.
2. A method of producing a tissue equivalent, the method comprising:
(a) forming a mixture comprising collagen and at least one contractile agent; and (b) applying the mixture obtained in step (a) to a collagen gel in contact with a permeable member, and maintaining the mixture and gel under conditions which permit formation of the tissue equivalent.
(a) forming a mixture comprising collagen and at least one contractile agent; and (b) applying the mixture obtained in step (a) to a collagen gel in contact with a permeable member, and maintaining the mixture and gel under conditions which permit formation of the tissue equivalent.
3. The method of claim 2, wherein the contractile agent comprises fibroblast cells.
4. The method of claim 2, wherein the mixture of step (a) contains fibroblast cells at a concentration of about 1.25 to 5 x 10 4 cells/ml and collagen at about 0.5 to 2.0 mg/ml.
5. The method of claim 2 wherein the collagen gel is prepared by casting a collagen solution comprising collagen at a concentration of about 0.5 to 2.0 mg/ml.
6. The method of claim 5, wherein the mixture of step (a) and the solution of step (b) are used at a ratio of about 3:1 to 1:3, volume: volume.
7. The method of claim 2, wherein an absorbent member is disposed adjacent the permeable member.
8. The method of claim 7, wherein the absorbent member comprises a fibrous pad or a gel.
9. The method of claim 8, wherein the fibrous pad is cotton.
10. The method of claim 2, wherein a gel comprising agarose is disposed adjacent the permeable member.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002298856A CA2298856C (en) | 1989-09-15 | 1990-08-24 | Living tissue equivalents |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40805289A | 1989-09-15 | 1989-09-15 | |
| US07/408,052 | 1989-09-15 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002298856A Division CA2298856C (en) | 1989-09-15 | 1990-08-24 | Living tissue equivalents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2023968A1 CA2023968A1 (en) | 1991-03-16 |
| CA2023968C true CA2023968C (en) | 2000-05-02 |
Family
ID=23614662
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002298856A Expired - Fee Related CA2298856C (en) | 1989-09-15 | 1990-08-24 | Living tissue equivalents |
| CA002023968A Expired - Fee Related CA2023968C (en) | 1989-09-15 | 1990-08-24 | Living tissue equivalents |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002298856A Expired - Fee Related CA2298856C (en) | 1989-09-15 | 1990-08-24 | Living tissue equivalents |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US5536656A (en) |
| EP (1) | EP0418035B1 (en) |
| JP (1) | JPH03151977A (en) |
| KR (1) | KR940001379B1 (en) |
| AT (1) | ATE119194T1 (en) |
| AU (1) | AU6215690A (en) |
| CA (2) | CA2298856C (en) |
| DE (1) | DE69017324T2 (en) |
| DK (1) | DK0418035T3 (en) |
| ES (1) | ES2071778T3 (en) |
| IE (1) | IE903340A1 (en) |
| IL (1) | IL95429A (en) |
Families Citing this family (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5888720A (en) * | 1992-10-27 | 1999-03-30 | Yissum Research And Development Company Of The Hebrew University Of Jerusalem | In vitro micro-organs |
| CA2119064A1 (en) * | 1993-03-17 | 1994-09-18 | Richard A. Berg | Dermal-epidermal in vitro test system |
| GB9306449D0 (en) * | 1993-03-29 | 1993-05-19 | Nat Heart Research Fund | Tissue equivalents |
| ATE310839T1 (en) * | 1994-04-29 | 2005-12-15 | Scimed Life Systems Inc | STENT WITH COLLAGEN |
| US5665114A (en) * | 1994-08-12 | 1997-09-09 | Meadox Medicals, Inc. | Tubular expanded polytetrafluoroethylene implantable prostheses |
| US5891558A (en) * | 1994-11-22 | 1999-04-06 | Tissue Engineering, Inc. | Biopolymer foams for use in tissue repair and reconstruction |
| US6419920B1 (en) | 1995-10-25 | 2002-07-16 | Trans Karyotic Therapies, Inc. | Hybrid matrix implants and explants |
| US5965125A (en) | 1995-10-25 | 1999-10-12 | Transkaryotic Therapies, Inc. | Hybrid matrix implants and explants |
| US5955353A (en) * | 1997-05-22 | 1999-09-21 | Excorp Medical, Inc. | Hollow fiber bioreactor with an extrafilament flow plug |
| US20020086423A1 (en) * | 1997-09-09 | 2002-07-04 | Toshiaki Takezawa | Hydrogel thin film containing extracellular matrix components |
| AU3077299A (en) | 1998-03-11 | 1999-09-27 | University Of Southern California | Method of promoting production of living tissue equivalents |
| US6129757A (en) * | 1998-05-18 | 2000-10-10 | Scimed Life Systems | Implantable members for receiving therapeutically useful compositions |
| AU769637B2 (en) * | 1998-11-19 | 2004-01-29 | Organogenesis Inc. | Bioengineered tissue constructs and methods for producing and using them |
| US7001746B1 (en) * | 1999-01-29 | 2006-02-21 | Artecel Sciences, Inc. | Methods and compositions for the differentiation of human preadipocytes into adipocytes |
| US6479072B1 (en) * | 1999-02-11 | 2002-11-12 | The General Hospital Corporation | Microfabricated membranes and matrices |
| US6197061B1 (en) * | 1999-03-01 | 2001-03-06 | Koichi Masuda | In vitro production of transplantable cartilage tissue cohesive cartilage produced thereby, and method for the surgical repair of cartilage damage |
| ATE373079T1 (en) | 1999-06-21 | 2007-09-15 | Gen Hospital Corp | CELL CULTURE SYSTEMS AND METHODS FOR ORGAN SUPPORT FACILITIES |
| WO2001014527A1 (en) * | 1999-08-23 | 2001-03-01 | Organogenesis Inc. | Skin care compositions and treatments |
| US7582292B2 (en) | 2000-02-26 | 2009-09-01 | Artecel, Inc. | Adipose tissue derived stromal cells for the treatment of neurological disorders |
| EP1918366A1 (en) | 2000-02-26 | 2008-05-07 | Artecel, Inc. | Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof |
| ATE384124T1 (en) * | 2000-02-26 | 2008-02-15 | Artecel Inc | PLURIPOTENT STEM CELLS CREATED FROM ADIATIVE TISSUE STROMAL CELLS AND THEIR USES |
| DK1290145T3 (en) | 2000-05-31 | 2006-03-13 | Fraunhofer Ges Forschung | Three-dimensional skin model |
| AU6904101A (en) * | 2000-05-31 | 2001-12-11 | Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. | Infection model |
| US7144729B2 (en) | 2000-09-01 | 2006-12-05 | Dfb Pharmaceuticals, Inc. | Methods and compositions for tissue regeneration |
| US7597712B2 (en) | 2000-09-18 | 2009-10-06 | Organogenesis, Inc. | Method for treating a patient using a cultured connective tissue construct |
| EP1832300A3 (en) * | 2000-09-18 | 2008-02-27 | Organogenesis Inc. | Method for treating a patient using a cultured connective tissue construct |
| US7041868B2 (en) | 2000-12-29 | 2006-05-09 | Kimberly-Clark Worldwide, Inc. | Bioabsorbable wound dressing |
| EP1404809B1 (en) * | 2001-03-02 | 2013-12-11 | Stratatech Corporation | Improved skin substitutes and uses thereof |
| US6974697B2 (en) * | 2001-03-02 | 2005-12-13 | Stratech Corporation | Skin substitutes with improved barrier function |
| US20030211793A1 (en) * | 2001-03-05 | 2003-11-13 | Eugene Bell | Injectable bio-compatible material and methods of use |
| JP3960969B2 (en) | 2001-06-14 | 2007-08-15 | ミリポア・コーポレイション | Tray with protrusion |
| AU2002335747B2 (en) * | 2001-09-15 | 2009-01-29 | Rush University Medical Center | Stratified cartilage tissue and methods to engineer same |
| US20030165473A1 (en) * | 2001-11-09 | 2003-09-04 | Rush-Presbyterian-St. Luke's Medical Center | Engineered intervertebral disc tissue |
| WO2003072128A2 (en) * | 2002-02-22 | 2003-09-04 | Ebi, L.P. | Methods and compositions for treating bone or cartilage defects |
| US7741116B2 (en) | 2002-03-06 | 2010-06-22 | University Of Cincinnati | Surgical device for skin therapy or testing |
| IL164817A0 (en) | 2002-04-30 | 2005-12-18 | Stratatech Corp | Keratinocytes expressing exogenous angiogenic growth factors |
| US7229820B2 (en) * | 2002-06-13 | 2007-06-12 | Wilson Wolf Manufacturing Corporation | Apparatus and method for culturing and preserving tissue constructs |
| US7462448B2 (en) * | 2002-08-02 | 2008-12-09 | Stratatech Corporation | Species specific DNA detection |
| EP3100611B1 (en) | 2003-08-01 | 2018-09-12 | Stratatech Corporation | Human skin equivalents expressing exogenous polypeptides |
| FR2881434B1 (en) * | 2005-02-02 | 2007-05-11 | Coletica Sa | DEVICE FOR SUPPORTING CELL CULTURE |
| CA2600177C (en) | 2005-03-01 | 2011-06-14 | Stratatech Corporation | Human skin equivalents expressing exogenous polypeptides |
| JP2008532550A (en) | 2005-03-17 | 2008-08-21 | ストラタテック コーポレーション | Skin substitute with improved purity |
| FR2889808B1 (en) | 2005-08-17 | 2011-07-22 | Oreal | USE OF 8-HEXADECENE-1,16-DICARBOXYLIC ACID AS A CARE AGENT TO PROMOTE COHESION OF THE CORNEA LAYER |
| AU2007223276B2 (en) * | 2006-03-03 | 2012-12-20 | Organogenesis, Inc. | Oral tissue regeneration and repair |
| FR2903702B1 (en) | 2006-07-13 | 2012-10-19 | Oreal | EQUIVALENT OF EPIDERM CAPABLE OF PIGMENTING OBTAINED FROM CELLS OF THE MATRIX, PROCESS FOR THEIR PREPARATION AND USE |
| US8932619B2 (en) * | 2007-06-27 | 2015-01-13 | Sofradim Production | Dural repair material |
| US20090068250A1 (en) | 2007-09-07 | 2009-03-12 | Philippe Gravagna | Bioresorbable and biocompatible compounds for surgical use |
| WO2009043052A1 (en) * | 2007-09-27 | 2009-04-02 | Columbia University | Methods and systems for forming biocompatible materials |
| EP2215212B1 (en) | 2007-11-14 | 2017-08-30 | Stratatech Corporation | Cold storage of organotypically cultured skin equivalents for clinical applications |
| US9308068B2 (en) | 2007-12-03 | 2016-04-12 | Sofradim Production | Implant for parastomal hernia |
| PL2288376T3 (en) | 2008-04-18 | 2016-07-29 | Collplant Ltd | Methods of generating and using procollagen |
| US9242026B2 (en) | 2008-06-27 | 2016-01-26 | Sofradim Production | Biosynthetic implant for soft tissue repair |
| EP2350259A4 (en) * | 2008-10-22 | 2013-12-18 | Regenemed Inc | Culture systems |
| DK2352472T3 (en) | 2008-11-04 | 2017-04-10 | Stratatech Corp | Dried and irradiated skin equivalents ready to use |
| US9511093B2 (en) * | 2009-03-23 | 2016-12-06 | The Texas A & M University System | Compositions of mesenchymal stem cells to regenerate bone |
| US20100330046A1 (en) * | 2009-05-21 | 2010-12-30 | Stratatech Corporation | Human skin substitutes expressing il-12 |
| US9321988B2 (en) * | 2009-06-18 | 2016-04-26 | Illinois Tool Works Inc. | Gas and liquid tissue culture interface |
| FR2949688B1 (en) | 2009-09-04 | 2012-08-24 | Sofradim Production | FABRIC WITH PICOTS COATED WITH A BIORESORBABLE MICROPOROUS LAYER |
| SG184385A1 (en) * | 2010-04-05 | 2012-11-29 | Emd Millipore Corp | Polymeric membranes with human skin like permeability properties and uses thereof |
| FR2967163A1 (en) | 2010-11-05 | 2012-05-11 | Centre Nat Rech Scient | IN VITRO OR EX VIVO METHOD FOR SURVIVAL MAINTENANCE AND GENERATION OR RECONSTRUCTION OF AN EPIDERM |
| FR2972626B1 (en) | 2011-03-16 | 2014-04-11 | Sofradim Production | PROSTHETIC COMPRISING A THREE-DIMENSIONAL KNIT AND ADJUSTED |
| FR2976001B1 (en) | 2011-05-30 | 2014-10-31 | Oreal | RECONSTRUCTED SCALP LEATHER MODEL AND METHOD FOR SCREENING ACTIVE MOLECULES |
| FR2977789B1 (en) | 2011-07-13 | 2013-07-19 | Sofradim Production | PROSTHETIC FOR UMBILIC HERNIA |
| FR2977790B1 (en) | 2011-07-13 | 2013-07-19 | Sofradim Production | PROSTHETIC FOR UMBILIC HERNIA |
| WO2013046058A2 (en) | 2011-09-30 | 2013-04-04 | Sofradim Production | Reversible stiffening of light weight mesh |
| AU2012313983B2 (en) | 2011-09-30 | 2017-01-19 | Sofradim Production | Multilayer implants for delivery of therapeutic agents |
| FR2985271B1 (en) | 2011-12-29 | 2014-01-24 | Sofradim Production | KNITTED PICOTS |
| FR2985170B1 (en) | 2011-12-29 | 2014-01-24 | Sofradim Production | PROSTHESIS FOR INGUINAL HERNIA |
| FR2994185B1 (en) | 2012-08-02 | 2015-07-31 | Sofradim Production | PROCESS FOR THE PREPARATION OF A POROUS CHITOSAN LAYER |
| PL226837B1 (en) | 2012-08-24 | 2017-09-29 | Celther Polska Spółka Z Ograniczoną Odpowiedzialnością | Active polymer layer formed of chitin derivatives, especially for dressing and its use |
| FR2995778B1 (en) | 2012-09-25 | 2015-06-26 | Sofradim Production | ABDOMINAL WALL REINFORCING PROSTHESIS AND METHOD FOR MANUFACTURING THE SAME |
| FR2995788B1 (en) | 2012-09-25 | 2014-09-26 | Sofradim Production | HEMOSTATIC PATCH AND PREPARATION METHOD |
| FR2995779B1 (en) | 2012-09-25 | 2015-09-25 | Sofradim Production | PROSTHETIC COMPRISING A TREILLIS AND A MEANS OF CONSOLIDATION |
| AU2013322268B2 (en) | 2012-09-28 | 2017-08-31 | Sofradim Production | Packaging for a hernia repair device |
| ES2705043T3 (en) | 2013-03-13 | 2019-03-21 | Stratatech Corp | Cryopreservation of viable human skin substitutes |
| AU2014259787B2 (en) | 2013-05-03 | 2018-03-08 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Skin substitutes and methods for hair follicle neogenesis |
| FR3006581B1 (en) | 2013-06-07 | 2016-07-22 | Sofradim Production | PROSTHESIS BASED ON TEXTILE FOR LAPAROSCOPIC PATHWAY |
| FR3006578B1 (en) | 2013-06-07 | 2015-05-29 | Sofradim Production | PROSTHESIS BASED ON TEXTILE FOR LAPAROSCOPIC PATHWAY |
| WO2015166455A1 (en) | 2014-04-30 | 2015-11-05 | Fondazione Istituto Italiano Di Tecnologia | Method for producing a totally endogenous bioengineered tissue and tissue obtained thereby |
| EP3000489B1 (en) | 2014-09-24 | 2017-04-05 | Sofradim Production | Method for preparing an anti-adhesion barrier film |
| EP3000433B1 (en) | 2014-09-29 | 2022-09-21 | Sofradim Production | Device for introducing a prosthesis for hernia treatment into an incision and flexible textile based prosthesis |
| EP3000432B1 (en) | 2014-09-29 | 2022-05-04 | Sofradim Production | Textile-based prosthesis for treatment of inguinal hernia |
| EP3029189B1 (en) | 2014-12-05 | 2021-08-11 | Sofradim Production | Prosthetic porous knit, method of making same and hernia prosthesis |
| EP3059255B1 (en) | 2015-02-17 | 2020-05-13 | Sofradim Production | Method for preparing a chitosan-based matrix comprising a fiber reinforcement member |
| EP3085337B1 (en) | 2015-04-24 | 2022-09-14 | Sofradim Production | Prosthesis for supporting a breast structure |
| ES2676072T3 (en) | 2015-06-19 | 2018-07-16 | Sofradim Production | Synthetic prosthesis comprising a knitted fabric and a non-porous film and method of forming it |
| EP3195830B1 (en) | 2016-01-25 | 2020-11-18 | Sofradim Production | Prosthesis for hernia repair |
| FR3054449B1 (en) | 2016-07-29 | 2018-08-31 | L'oreal | EQUIVALENT OF SKIN WITH DERMAL COMPARTMENTS SEPARATE JUXTAPOSES |
| EP3312325B1 (en) | 2016-10-21 | 2021-09-22 | Sofradim Production | Method for forming a mesh having a barbed suture attached thereto and the mesh thus obtained |
| EP3398554A1 (en) | 2017-05-02 | 2018-11-07 | Sofradim Production | Prosthesis for inguinal hernia repair |
| WO2018220137A1 (en) * | 2017-05-31 | 2018-12-06 | ETH Zürich | Assembly for the production of tissue implants |
| FR3071512B1 (en) | 2017-09-28 | 2022-02-25 | Oreal | MOLECULAR SIGNATURES OF THREE SUB-POPULATIONS OF DERMAL FIBROBLASTS AND DERMIS EQUIVALENT COMPRISING ONE OF THESE SUB-POPULATIONS |
| EP3653171A1 (en) | 2018-11-16 | 2020-05-20 | Sofradim Production | Implants suitable for soft tissue repair |
| FR3111904B1 (en) | 2020-06-30 | 2022-10-21 | Oreal | Bioink for bioprinting of an invaginated dermal-epidermal junction model |
| LU502391B1 (en) | 2022-06-28 | 2024-01-09 | Univerza V Mariboru | A complex in vitro model of human skin, a process for preparation and use thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2677646A (en) * | 1952-03-22 | 1954-05-04 | Lovell Chemical Company | Unit for bacterial analysis |
| US2761813A (en) * | 1953-01-21 | 1956-09-04 | Goetz Alexander | Means and method of producing and controlling cultures of microorganisms |
| GB1594389A (en) * | 1977-06-03 | 1981-07-30 | Max Planck Gesellschaft | Dressing material for wounds |
| JPS55501130A (en) * | 1978-12-26 | 1980-12-18 | ||
| US4290911A (en) * | 1979-02-07 | 1981-09-22 | Fmc Corporation | Agarose composition, aqueous gel and method of making same |
| SE7908454L (en) * | 1979-10-11 | 1981-04-12 | Pharmacia Fine Chemicals Ab | ISOELECTRIC FOCUS MEDIUM |
| US4539716A (en) * | 1981-03-19 | 1985-09-10 | Massachusetts Institute Of Technology | Fabrication of living blood vessels and glandular tissues |
| US4546500A (en) * | 1981-05-08 | 1985-10-15 | Massachusetts Institute Of Technology | Fabrication of living blood vessels and glandular tissues |
| US4505266A (en) * | 1981-10-26 | 1985-03-19 | Massachusetts Institute Of Technology | Method of using a fibrous lattice |
| US4485096A (en) * | 1982-02-26 | 1984-11-27 | Massachusetts Institute Of Technology | Tissue-equivalent and method for preparation thereof |
| US4485097A (en) * | 1982-05-26 | 1984-11-27 | Massachusetts Institute Of Technology | Bone-equivalent and method for preparation thereof |
| US4598045A (en) * | 1982-08-25 | 1986-07-01 | Hana Biologics, Inc. | Triphasic mycoplasmatales detection method |
| US4734372A (en) * | 1983-02-04 | 1988-03-29 | Brown University Research Foundation | Cell culturing methods and apparatus |
| US4578354A (en) * | 1983-05-09 | 1986-03-25 | Pfizer Inc. | Immobilization of catalytically active microorganisms in agar gel fibers |
| DE3584188D1 (en) * | 1984-05-11 | 1991-10-31 | Terumo Corp | METHOD FOR PRODUCING A SYNTETIC RESIN CONTAINER. |
| US4604346A (en) * | 1984-10-09 | 1986-08-05 | Massachusetts Institute Of Technology | Skin-equivalent prepared by the use of punch biopsy |
| JPS6225974A (en) * | 1985-07-25 | 1987-02-03 | Asahi Chem Ind Co Ltd | Gelatinous composition consisting of collagen |
| US5026649A (en) * | 1986-03-20 | 1991-06-25 | Costar Corporation | Apparatus for growing tissue cultures in vitro |
| US5032508A (en) * | 1988-09-08 | 1991-07-16 | Marrow-Tech, Inc. | Three-dimensional cell and tissue culture system |
| US4963489A (en) * | 1987-04-14 | 1990-10-16 | Marrow-Tech, Inc. | Three-dimensional cell and tissue culture system |
| US5037656A (en) * | 1986-12-04 | 1991-08-06 | Millipore Corporation | Porous membrane having hydrophilic and cell growth promotions surface and process |
| FR2612939B1 (en) * | 1987-03-26 | 1989-06-23 | Cird | SKIN EQUIVALENT |
| FR2612938B1 (en) * | 1987-03-26 | 1989-06-23 | Cird | METHOD FOR OBTAINING A SKIN EQUIVALENT AND CORRESPONDING SKIN EQUIVALENT |
| US4835102A (en) * | 1987-03-31 | 1989-05-30 | Eugene Bell | Tissue equivalent test systems |
| US4837379A (en) * | 1988-06-02 | 1989-06-06 | Organogenesis Inc. | Fibrin-collagen tissue equivalents and methods for preparation thereof |
| US4996154A (en) * | 1989-05-04 | 1991-02-26 | Millipore Corporation | Method for growing cellular tissue |
| US4912057A (en) * | 1989-06-13 | 1990-03-27 | Cancer Diagnostics, Inc. | Cell chamber for chemotaxis assay |
-
1990
- 1990-08-20 IL IL95429A patent/IL95429A/en not_active IP Right Cessation
- 1990-08-24 CA CA002298856A patent/CA2298856C/en not_active Expired - Fee Related
- 1990-08-24 CA CA002023968A patent/CA2023968C/en not_active Expired - Fee Related
- 1990-09-05 AU AU62156/90A patent/AU6215690A/en not_active Abandoned
- 1990-09-11 DE DE69017324T patent/DE69017324T2/en not_active Expired - Lifetime
- 1990-09-11 DK DK90309942.2T patent/DK0418035T3/en active
- 1990-09-11 ES ES90309942T patent/ES2071778T3/en not_active Expired - Lifetime
- 1990-09-11 AT AT90309942T patent/ATE119194T1/en not_active IP Right Cessation
- 1990-09-11 EP EP90309942A patent/EP0418035B1/en not_active Expired - Lifetime
- 1990-09-14 IE IE334090A patent/IE903340A1/en not_active IP Right Cessation
- 1990-09-14 JP JP2246000A patent/JPH03151977A/en active Granted
- 1990-09-14 KR KR1019900014547A patent/KR940001379B1/en not_active IP Right Cessation
-
1994
- 1994-02-09 US US08/193,809 patent/US5536656A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DK0418035T3 (en) | 1995-07-10 |
| IL95429A (en) | 1997-09-30 |
| DE69017324T2 (en) | 1995-08-03 |
| ATE119194T1 (en) | 1995-03-15 |
| CA2023968A1 (en) | 1991-03-16 |
| IE903340A1 (en) | 1991-04-10 |
| KR910005893A (en) | 1991-04-27 |
| IL95429A0 (en) | 1991-06-30 |
| KR940001379B1 (en) | 1994-02-21 |
| ES2071778T3 (en) | 1995-07-01 |
| US5536656A (en) | 1996-07-16 |
| CA2298856A1 (en) | 1991-03-16 |
| CA2298856C (en) | 2004-11-16 |
| EP0418035B1 (en) | 1995-03-01 |
| DE69017324D1 (en) | 1995-04-06 |
| AU6215690A (en) | 1991-08-01 |
| JPH03151977A (en) | 1991-06-28 |
| EP0418035A1 (en) | 1991-03-20 |
| JPH0553505B2 (en) | 1993-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2023968C (en) | Living tissue equivalents | |
| EP2639293B1 (en) | Cell culture chamber, method for producing same, tissue model using cell culture chamber, and method for producing same | |
| Guo et al. | Basement membrane and human epidermal differentiation in vitro | |
| US4837379A (en) | Fibrin-collagen tissue equivalents and methods for preparation thereof | |
| AU719160B2 (en) | Submucosa as a growth substrate for cells | |
| US6051425A (en) | Method for producing tissue formation and tissue culture kit | |
| JP3493199B2 (en) | Implantable prosthesis, kit and device for manufacturing the same | |
| Bernstam et al. | Keratinocytes grown at the air-liquid interface | |
| ES2252259T3 (en) | THREE-DIMENSIONAL SKIN MODEL. | |
| AU2003269328A1 (en) | Fibrin cell supports and methods of use thereof | |
| WO2005014774A1 (en) | Carrier for culturing animal cell, and method for culturing or transplanting animal cell using said carrier for culture | |
| JP2005305177A (en) | Artificial tissue including tissue ancillary organ-like structure and its manufacturing method | |
| JP3951148B2 (en) | Artificial skin containing skin appendage-like structure and method for producing the same | |
| WO1992010217A1 (en) | Wound dressings and processes for manufacture thereof | |
| Sanmano et al. | Engraftment of umbilical cord epithelial cells in athymic mice: in an attempt to improve reconstructed skin equivalents used as epithelial composite | |
| US9259445B2 (en) | Integrated implant system (IIS) biocompatible, biodegradable and bioactive, comprising a biocompatible sterile porous polymeric matrix and a gel, integrating in situ the tridimensional matrix structure | |
| Doolin et al. | Effects of microgravity on growing cultured skin constructs | |
| CN109722410B (en) | 3D full-layer skin model, culture medium for forming same and preparation method | |
| JPH10136977A (en) | Artificial tissue containing tissue-attached organ-like structure and its production | |
| US6043079A (en) | Cell growth apparatus for histophysiologic culture | |
| Leighton et al. | Organoid structure of normal rat bladder in unilaminar and bilaminar histophysiologic gradient culture: methods and observations | |
| KR101291830B1 (en) | Construction method for artificial skin containing cervi cornus colla | |
| Sahle et al. | A Fibrin‐Based Human Multicellular Gingival 3D Model Provides Biomimicry and Enables Long‐Term In Vitro Studies | |
| JPH02113885A (en) | Preparation of epithelial cell cultured in multiple layers | |
| Minuth et al. | Microreactor optimisation for functional tissue engineering |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |